Clinical Impact of the AISF STEPS ‐ MASH Algorithm: Real‐World Application in Tertiary Hepatology Practice
Liver International · 2026-12 · 46 (12)
DOI: 10.1111/liv.70956 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 16.11.2026. Verfasst von Nicola Pugliese und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. Hauptthemen laut MEDLINE: Algorithms, Non-alcoholic Fatty Liver Disease, Liver Cirrhosis, Fatty Liver. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Ministero della Salute.
Abstract (Originalsprache)
Background and Aims The approval of resmetirom and semaglutide for non‐cirrhotic people living with metabolic dysfunction‐associated steatohepatitis (MASH) and significant fibrosis has created a need for pragmatic strategies to identify treatment candidates in routine practice. We assessed the real‐world applicability of the AISF STEPS‐MASH algorithm and characterised the treatment status of people reaching final assessment in tertiary hepatology centres.
Methods
We retrospectively applied the AISF STEPS‐MASH algorithm to all consecutive adults undergoing vibration‐controlled transient elastography (VCTE) at nine Italian tertiary hepatology centres between January and June 2025. Step S defined a broad screening pool (controlled attenuation parameter [CAP] ≥ 248 dB/m and/or a metabolic referral indication). People with CAP‐defined steatosis, at least one cardiometabolic risk factor or metabolic referral indication, and no documented competing liver disease aetiology were assigned to the Primary pathway; all others were analysed separately as the Non‐primary pathway. Step T applied liver stiffness measurement (LSM) ≥ 8.0 kPa, excluding LSM ≥ 20.0 kPa and/or platelet count < 150 × 10 9 /L. Step E classified safety‐related conditions as label‐defined contraindications, warnings requiring monitoring, or interactions requiring treatment modification or temporary deferral. Stepwise attrition across Steps S, T and E was quantified.
Results
Of 8194 people screened, 8150 (99.5%) had paired CAP and LSM data. Step S criteria were met by 4371 (53.6%), of whom 2300 entered the Primary pathway and 2071 the Non‐primary pathway. Initial Step T criteria were met by 1041 people (23.8% of Step S; 12.8% of the evaluable cohort), and 750 reached the final Step T population after excluding 291 people with LSM ≥ 20.0 kPa and/or thrombocytopenia: 458 Primary and 292 Non‐primary. Within the final Step T Primary pathway, 317 people (69.2%) had a treatment status compatible with both drugs without modification, 140 (30.6%) required medication or clinical optimisation, and one (0.2%) had a formal contraindication. The Non‐primary pathway contained an adjudication reservoir of 191 people with an operational MASLD phenotype and a competing aetiology. The final Step T Primary pathway corresponded to 56.2 people per 1000 evaluable VCTE examinations, approximately one in every 18.
Conclusions
In tertiary hepatology practice, the AISF STEPS‐MASH algorithm translated broad VCTE activity into a focused treatment‐assessment population. Nearly one third of those assessed required medication or clinical optimisation before treatment, a proportion likely to vary across clinical settings, and the pathway also identified people requiring advanced liver disease surveillance or aetiological adjudication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.
- Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
- Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Division of Gastroenterology and Hepatology, Department of Medical Sciences, University of Turin, Turin, Italy.
- Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
- SC Medicina Indirizzo Metabolico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
ORCID-Profile: Nicola Pugliese, Roberta D'Ambrosio, Angelo Armandi, Antonio Liguori, Rosa Lombardi, Francesca Terracciani, Grazia Pennisi, Anna Mantovani, Andrea Dalbeni, Riccardo Perbellini, Federico Perna, Umberto Vespasiani Gentilucci, Anna Fracanzani, Luca Miele, Pietro Lampertico, Fabio Piscaglia, Alessio Aghemo, Salvatore Petta, Federico Ravaioli
Förderung
- Italian Ministry of Health
- Ministero della Salute
Zitieren
APA
Pugliese, N., D'Ambrosio, R., Armandi, A., Liguori, A., Lombardi, R., Terracciani, F., Pennisi, G., Mantovani, A., Dalbeni, A., Ferri, S., Perbellini, R., Maffi, G., Perna, F., Gentilucci, U. V., Fracanzani, A., Miele, L., Bugianesi, E., Lampertico, P., Piscaglia, F., …, & Ravaioli, F. (2026). Clinical Impact of the AISF STEPS ‐ MASH Algorithm: Real‐World Application in Tertiary Hepatology Practice. Liver International, 46(12). https://doi.org/10.1111/liv.70956
Vancouver
Pugliese N, D'Ambrosio R, Armandi A, Liguori A, Lombardi R, Terracciani F, et al. Clinical Impact of the AISF STEPS ‐ MASH Algorithm: Real‐World Application in Tertiary Hepatology Practice. Liver International. 2026;46(12). doi:10.1111/liv.70956
BibTeX
@article{Pugliese2026,
author = {Pugliese, Nicola and D'Ambrosio, Roberta and Armandi, Angelo and Liguori, Antonio and Lombardi, Rosa and Terracciani, Francesca and Pennisi, Grazia and Mantovani, Anna and Dalbeni, Andrea and Ferri, Silvia and Perbellini, Riccardo and Maffi, Gabriele and Perna, Federico and Gentilucci, Umberto Vespasiani and Fracanzani, Anna and Miele, Luca and Bugianesi, Elisabetta and Lampertico, Pietro and Piscaglia, Fabio and Aghemo, Alessio and Petta, Salvatore and Ravaioli, Federico},
title = {Clinical Impact of the AISF STEPS ‐ MASH Algorithm: Real‐World Application in Tertiary Hepatology Practice},
journal = {Liver International},
year = {2026},
volume = {46},
number = {12},
doi = {10.1111/liv.70956}
}
EUVIMED